Thrombotic thrombocytopenic purpura: Reducing the risk?

Michael Berndt, Robert Andrews

Research output: Contribution to journalLetterOther

5 Citations (Scopus)

Abstract

von Willebrand factor (vWF) has a key role in initiating platelet aggregation, and thereby thrombus formation, that is dependent on its ability to form appropriately sized multimers. Ultralarge multimers promote the formation of the microvascular thrombi that are hallmarks of the life-threatening condition thrombotic thrombocytopenic purpura (TTP). In this issue of the JCI, Chen et al. show that the drug N-acetylcysteine (NAC) can decrease the size of vWF multimers in vitro and in vivo, resolving thrombi in mice. These data suggest that NAC could potentially be used to treat thrombotic conditions such as TTP.
Original languageEnglish
Pages (from-to)522 - 524
Number of pages3
JournalEuropean Journal of Clinical Investigation
Volume121
Issue number2
DOIs
Publication statusPublished - 2011

Cite this

@article{9ff9ec8aeacc41d0beebdd7af779d533,
title = "Thrombotic thrombocytopenic purpura: Reducing the risk?",
abstract = "von Willebrand factor (vWF) has a key role in initiating platelet aggregation, and thereby thrombus formation, that is dependent on its ability to form appropriately sized multimers. Ultralarge multimers promote the formation of the microvascular thrombi that are hallmarks of the life-threatening condition thrombotic thrombocytopenic purpura (TTP). In this issue of the JCI, Chen et al. show that the drug N-acetylcysteine (NAC) can decrease the size of vWF multimers in vitro and in vivo, resolving thrombi in mice. These data suggest that NAC could potentially be used to treat thrombotic conditions such as TTP.",
author = "Michael Berndt and Robert Andrews",
year = "2011",
doi = "10.1172/JCI46091",
language = "English",
volume = "121",
pages = "522 -- 524",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "2",

}

Thrombotic thrombocytopenic purpura: Reducing the risk? / Berndt, Michael; Andrews, Robert.

In: European Journal of Clinical Investigation, Vol. 121, No. 2, 2011, p. 522 - 524.

Research output: Contribution to journalLetterOther

TY - JOUR

T1 - Thrombotic thrombocytopenic purpura: Reducing the risk?

AU - Berndt, Michael

AU - Andrews, Robert

PY - 2011

Y1 - 2011

N2 - von Willebrand factor (vWF) has a key role in initiating platelet aggregation, and thereby thrombus formation, that is dependent on its ability to form appropriately sized multimers. Ultralarge multimers promote the formation of the microvascular thrombi that are hallmarks of the life-threatening condition thrombotic thrombocytopenic purpura (TTP). In this issue of the JCI, Chen et al. show that the drug N-acetylcysteine (NAC) can decrease the size of vWF multimers in vitro and in vivo, resolving thrombi in mice. These data suggest that NAC could potentially be used to treat thrombotic conditions such as TTP.

AB - von Willebrand factor (vWF) has a key role in initiating platelet aggregation, and thereby thrombus formation, that is dependent on its ability to form appropriately sized multimers. Ultralarge multimers promote the formation of the microvascular thrombi that are hallmarks of the life-threatening condition thrombotic thrombocytopenic purpura (TTP). In this issue of the JCI, Chen et al. show that the drug N-acetylcysteine (NAC) can decrease the size of vWF multimers in vitro and in vivo, resolving thrombi in mice. These data suggest that NAC could potentially be used to treat thrombotic conditions such as TTP.

U2 - 10.1172/JCI46091

DO - 10.1172/JCI46091

M3 - Letter

VL - 121

SP - 522

EP - 524

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 2

ER -